Total trials
95
Active
20
Phase 3
8
Total enrollment
115,574
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Cladribine s.c. injection, HCL treatment | — | — | — | — | — | 1 | |
| Ranibizumab | — | — | — | — | — | 1 |
Next readouts
- 2025-12
- 2027-11-30
Top conditions
- Acute Kidney Injury11
- Pulmonary Hypertension11
- Heart Failure5
- Dysphagia4
- Stroke4
- Pulmonary Arterial Hypertension3
- ARDS3
- Stroke, Acute3
Frequently asked questions about University of Giessen
- How many clinical trials does University of Giessen have on ClinicalTrials.gov?
- University of Giessen is listed as the lead sponsor on 95 clinical trials in ClinicalTrials.gov, 20 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Giessen's trials are in Phase 3?
- 8 of University of Giessen's trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does University of Giessen focus on?
- University of Giessen's most-studied conditions on ClinicalTrials.gov are Acute Kidney Injury, Pulmonary Hypertension, Heart Failure, Dysphagia, Stroke.
- When are University of Giessen's next clinical trial readouts?
- University of Giessen has 2 upcoming primary-completion readouts tracked here; the soonest is “Therapy Optimisation for the Treatment of Hairy Cell Leukemia”, expected around 2025-12.